Cyber Media (India) Fund Raise of ₹0.3 Cr

Cyber Media (India) Q2 FY27 Results: Net Profit ₹1 Cr, Up 11.1% YoY

Cyber Media (India) Ltd reported revenue from operations of ₹46.8 Cr (+93.4% YoY) and net profit of ₹1 Cr (+11.1% YoY) for Q2 FY27.

Key figure

Net profit ₹1 Cr · +11.1% YoY

Cyber Media (India) Acquisition

NCLT Delhi allowed the First Motion for Cyber Media Research & Services merger into Cyber Media (India). Shareholder and creditor meetings are directed to approve the scheme.

Cyber Media (India) Board Meeting Date

Cyber Media (India) Limited notified a board meeting on 26 Oct 2026 to consider Q1 FY27 unaudited results. No financial figures are disclosed in this advance intimation.

Cyber Media (India) Other Announcement

The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026. This provides standard disclosures regarding shareholder ownership.

Cyber Media (India) Legal & Regulatory

Cyber Media (India) Limited received an assessment order from the Tamil Nadu Commercial Taxes Department demanding Rs. 0.97 Crore. The company intends to contest the tax demand legally.

Value

₹0.97 Cr

From

State Tax Officer, Commercial Taxes Department, Chennai

Cyber Media (India) Legal & Regulatory

Cyber Media (India) Limited received a tax demand order of ₹0.54 Crore from the Commercial Taxes Department. The company plans to legally contest the order.

Value

₹0.54 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr